Is It Too Late To Consider Amgen (AMGN) After Its Strong Multi Year Share Price Run?
- Investors may be wondering if Amgen’s share price still offers value after a strong run, or whether most of the opportunity is already reflected in the stock.
- The stock closed at US$335.94, with returns of 1.6% over the last week, a decline of 2.5% over the last month, and gains of 2.5% year to date, 23.8% over 1 year, 68.6% over 3 years, and 68.3% over 5 years.
- Recent headlines around Amgen continue to focus on its position as a large biotechnology company, including ongoing attention on its product portfolio and pipeline, regulatory milestones, and the broader sector backdrop. Together, these set the context for how the market is weighing its prospects against current pricing.
- Amgen currently has a valuation score of 4 out of 6,…
Source link
